secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2025-02-07T23:59:59+00:00
Accession:  0001558370-25-000715
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec's partner Norgine launches PEDMARQSI in Germany for cisplatin-induced hearing loss prevention
--------------------------------------------------------------------------------

- PEDMARQSI (sodium thiosulfate injection) launched in Germany by Norgine for prevention of ototoxicity in pediatric patients.
- First and only approved therapy in EU/UK for cisplatin-induced hearing loss in children 1 month to <18 years with localized solid tumors.
- License deal (March 2024) included $43M upfront, up to $230M in milestones, and double-digit tiered royalties (mid-teens to mid-twenties).
- Phase 3 data showed ~50% reduction in hearing loss vs. cisplatin alone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000155837025000715/0001558370-25-000715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000155837025000715/fencf-20250207x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer